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Spinocerebellar ataxia type 7 (SCA7) is caused by a toxic polyglutamine (polyQ) expansion in the N-terminus of the
protein ataxin-7. Ataxin-7 has a known function in the histone acetylase complex, Spt/Ada/Gcn5 acetylase (STAGA)
chromatin-remodeling complex. We hypothesized that some histone deacetylase (HDAC) family members would
impact the posttranslational modification of normal and expanded ataxin-7 and possibly modulate ataxin-7 function
or neurotoxicity associated with the polyQ expansion. Interestingly, when we coexpressed each HDAC family member
in the presence of ataxin-7 we found that HDAC3 increased the posttranslational modification of normal and expanded
ataxin-7. Specifically, HDAC3 stabilized ataxin-7 and increased modification of the protein. Further, HDAC3 physically
interacts with ataxin-7. The physical interaction of HDAC3 with normal and polyQ-expanded ataxin-7 affects the toxicity
in a polyQ-dependent manner. We detect robust HDAC3 expression in neurons and glia in the cerebellum and an
increase in the levels of HDAC3 in SCA7 mice. Consistent with this we found altered lysine acetylation levels and
deacetylase activity in the brains of SCA7 transgenic mice. This study implicates HDAC3 and ataxin-7 interaction as a
target for therapeutic intervention in SCA7, adding to a growing list of neurodegenerative diseases that may be treated
by HDAC inhibitors.
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Spinocerebellar ataxia type 7 (SCA7) is a rare neurode-
generative disease caused by a trinucleotide repeat ex-
pansion in the ataxin-7 gene [1-3]. SCA7 is one of nine
known polyglutamine (polyQ) diseases characterized by
aggregation of polyQ-expanded protein, nuclear inclu-
sions and repeat-dependent neuronal toxicity [4,5].
Ataxin-7 protein is ubiquitously expressed in the brain
with cytoplasmic and nuclear staining [6,7]. Ataxin-7
functions as part of two known transcriptional repressor
complexes: the Spt/Ada/Gcn5 acetylase (STAGA) chro-
matin remodeling complex with histone acetyltransferase
(HAT) activity [8]; and the TATA-BP free TAF-containing
complex (TFTC) [9,10]. In SCA7 patients there is in-
creased localization of ataxin-7 to discrete nuclear inclu-
sions [6,7,11,12]. Aggregation of polyglutamine-expanded* Correspondence: lellerby@buckinstitute.org
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reproduction in any medium, provided the orataxin-7 into the nucleus, concomitant with neurodegen-
eration and transcriptional deregulation, is also a feature
of SCA7 transgenic mouse models [13-16].
Transcriptional deregulation in polyglutamine diseases
has been associated with acetylation state changes, by al-
teration of the HAT activity of member complexes [17]
or by direct interaction of ataxins with histone deacety-
lases (HDACs), in particular HDAC3 [18,19]. HDAC3 is
an integral constituent of multiple co-repressor com-
plexes that activate HDAC3 and are recruited by tran-
scription factors to alter histone acetylation and repress
transcription [20-22]. HDAC3 shuttles between the cyto-
plasm and nucleus [23], altering activity of transcrip-
tional repressor complex target genes [24]. HDAC3 is
highly expressed in the brain [25] and is essential for
viability [26]. In cell studies, high levels of HDAC3 are
neurotoxic whereas HDAC3 suppression protects against
neuronal cell death [27]. Further, this appears to be a
modular switch in which HDAC3 interaction with
HDAC1 promotes survival or death [28]. This is consistentl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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itors, including those targeting HDAC3, in reducing
pathological behavioral phenotypes and neurodegenera-
tion in mouse models [29-32].
Previous work by our lab and others has shown that
ataxin-7 posttranslational modification (PTM) increases
ataxin-7 stability, effecting aggregation and toxicity of
the polyQ-expanded protein [16,33], with deacetylation
influencing stability of ataxin-7 although the enzyme
that was responsible for this effect was not determined.
In this study we found that HDAC3 enhanced PTMs
and the stability of ataxin-7, with evidence that ataxin-7
and HDAC3 physically interact and colocalize. Their asso-
ciation enhances cellular toxicity in a polyQ-dependent
manner. HDAC3 displays robust expression in neurons
and glia in the mouse cerebellum. We detect increased
levels of HDAC3 in SCA7 mice as well as altered lysine



















































































Figure 1 HDAC3 stabilizes ataxin-7 and enhances post-translational m
transiently transfected with HDAC constructs [2-8] in HEK293T cells for 72 h
tris gels. Western blot transfer and analysis with an antibody to ataxin-7 (PA
for the ataxin-7 stop constructs as well as bands of higher molecular weight i
GAPDH was used as a loading control. (B) Ataxin-7-10Q, ataxin-7-10Q (1–266)
ataxin-7-92Q (1–266) K257R were co-transfected with vector control or HDAC
(PA1-749) antibody revealed the presence of bands corresponding to the wild
molecular weight were dominant when ataxin-7 was co-transfected with HDA
SUMOylation-deficient ataxin-7 mutant (K257R). β-actin was used as a loadingSCA7 transgenic mice, indicating that the association
between HDAC3 and ataxin-7 may be a pathological fea-
ture of the disease.Results
HDAC3 effects ataxin-7 in a SCA7 cellular model
The effect of HDACs on ataxin-7 stability and post-
translational modifications was examined using a panel of
HDAC constructs co-expressed with the N-terminal frag-
ment of ataxin-7 (wild type and expanded) in HEK293T
cells [16]. HDAC3 co-expression had the most obvious
effect on ataxin-7 – upregulating the levels of ataxin-7 as
well as dramatically increasing the number of high mo-
lecular weight bands immunoreactive to the ataxin-7 anti-
body (Figure 1A). Other HDACs had much more subtle
effect on ataxin-7 stability and post-translational modifica-
















































































odifications. (A) Ataxin-7-10Q (1–266) and ataxin-7-92Q (1–266) were
rs. Lysates were collected and separated via SDS-PAGE on 4-12% bis-
1-749) revealed the presence of bands of expected molecular weight
ndicated by asterisks, particularly evident in the HDAC3 co-tranfection.
, ataxin-7-10Q (1–266) K257R, ataxin-7-92Q, ataxin-7-92Q (1–266) or
3 in HEK293T cells. Western blot analysis of cellular lysates with ataxin-7
type, expanded and ataxin-7 1–266 stop mutant. Bands of higher
C3 (indicated by asterisks). Note that these bands are diminished in the
control.
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amined further by western blotting of the full-length
ataxin-7, N-terminal fragments and a mutant resistant to
modification (K257R) (Figure 1B). HDAC3 co-expression
with both wild type ataxin-7-10Q and polyQ-expanded
ataxin-7-92Q lead to an increase in high-molecular weight
bands of ataxin-7 as well as a marked increase in protein
expression. While HDAC3 did increase the stability of
ataxin-7 K257R, post-translational modifications were
diminished, indicating that HDAC3 co-expression targets
































Figure 2 HDAC3 and ataxin-7 physically interact and colocalize. (A) Im
ataxin-7-10Q (wild type) or ataxin-7-92Q (expanded), or vector. Whole cell l
ataxin-7 (PA1-749), separated by SDS-PAGE and immunoblotted with an an
(B-12) and western blotting with ataxin-7 (K) supports the binding of ataxin
transfected with ataxin-7-10Q (wild type) or ataxin-7-92Q (expanded), and co-
ataxin-7 conjugated to Alexa 488 (green), HDAC3 conjugated to Alexa 555 (re
confocal microscopy to elucidate colocalization of ataxin-7 and HDAC3. ScaleAtaxin-7 physically interacts with HDAC3
Based on the enhanced stability of ataxin-7 in the pres-
ence of HDAC3, we determined whether ataxin-7 and
HDAC3 directly interact. Immunoprecipitation with an
antibody to ataxin-7, in cells expressing HDAC3 and
wild type or expanded ataxin-7, pulled down HDAC3
(Figure 2A). Interestingly, the polyQ-expanded ataxin-7
pulled down noticeably more HDAC3 than wild type
ataxin-7, although there is more polyQ-expanded ataxin-
7 present, as detected by ataxin-7 immunoblotting. Re-
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munoprecipitation of HEK293T cells transiently transfected with
ysates were subject to immunoprecipitation with an antibody to
tibody to HDAC3 (N-19). (B) Reverse immunoprecipation with HDAC3
-7 to HDAC3. (C) Immunocytochemistry of HEK293T cells transiently
transfected with HDAC3. Cells were fixed and stained with antibodies to
d), and counterstained with DAPI (blue). Cells were imaged using
bar represents 10 μm.
Duncan et al. Molecular Neurodegeneration 2013, 8:42 Page 4 of 14
http://www.molecularneurodegeneration.com/content/8/1/42wild type and expanded ataxin-7, again at elevated levels,
supporting the physical interaction of ataxin-7 and
HDAC3 that may be increased in the polyQ-expanded
mutant. Immunocytochemistry of co-transfected cells
revealed that HDAC3 was co-localized with both wild
type and expanded ataxin-7, particularly in the nucleus
(Figure 2B), consistent with our co-IP results. Consistent
with the physical interaction we see high-density ataxin-
7 staining in the nucleus upon ataxin-7-92Q expression,
indicative of the nuclear aggregates commonly detected
in SCA7 models (Figure 2C).
HDAC3 interaction modifies ataxin-7 subcellular
localization and cellular toxicity
During immunocytochemical co-localization studies we
noticed that ataxin-7 subcellular localization shifted upon
HDAC3 overexpression and so explored this in more de-
tail. Using biochemical subcellular fractionation, we found
that HDAC3 enhanced ataxin-7 stability and posttransla-
tional modifications in both cytoplasmic and nuclear frac-
tions for all ataxin-7 proteins expressed (Figure 3A,B).
With both the full-length and N-terminal fragments,
expanded ataxin-7 is more highly expressed than wild
type ataxin-7, consistent with enhanced stability of the
mutant form (Figure 3C). As expected ataxin-7 was found
both in the cytoplasm and nucleus of the transfected cells
(Figure 3C). Interestingly, the levels of ataxin-7 protein
are higher in both the cytoplasmic and nuclear fractions.
Quantification of the levels of ataxin-7-10Q or ataxin-
92Q in the nucleus demonstrated increased amounts of
the protein in the nucleus (3–5 fold increase) (Figure 3D).
This was due to increased expression of the protein in
the presence of HDAC3 and not a change in the relative
ratio of ataxin-7 protein in the nucleus relative to the
cytoplasm.
With reports from the literature of HDAC3 enhancing
neurotoxicity [27], we next evaluated whether increased
expression of ataxin-7-92Q impacted cell survival. By
immunocytochemistry using Hoescht staining we de-
tected a significant increase in the number of dying cells
upon HDAC3 co-expression in 293T cells (Figure 3E).
Expression of expanded ataxin-7 had more dying cells
(~48%) when compared to those expressing wild-type
ataxin-7 (36%). Transfected cells were counted as either
healthy, well-rounded nuclei or dying compact nuclei.
Bars represent the average percentage of dying cells
from four fields with n = 100 cells/field. Asterisks repre-
sent significant change between the ataxin-7 transfected
cells and those co-transfected with HDAC3. *:p < 0.05;
**:p < 0.01; ***:p < 0.005.
Role of deacetylase activity in HDAC3 effects on ataxin-7
In order to determine whether the effect of HDAC3 on
ataxin-7 stability, PTMs or localization depended on itsdeacetylase activity we used a catalytically-inactive HDAC3
mutant. Co-expression of this form of the HDAC3
(H134A/H135A) had the same effect on the stability of
ataxin-7 protein as wild type HDAC3 (Figure 4A). The
presence of ataxin-7 high molecular weight bands immu-
noreactive to ataxin-7 was similar in the presence of either
form of HDAC3 (Figure 4A). This was true for wild type
and expanded ataxin-7 as well as the N-terminal frag-
ments. Similarly, no effect was observed on the subcellular
localization of ataxin-7 as detected by immunocytochem-
istry (Figure 4B).
HDAC3 in mouse brain
Given our findings of HDAC3 interaction with ataxin-7
and regulation in vitro, we next looked at HDAC3 ex-
pression in vivo. In order to determine if HDAC3 was
expressed in regions non-transgenic of interest in SCA7
mice, we first defined HDAC3 regional and cellular
localization in nontransgenic mouse brain. Immunohis-
tochemical analysis of HDAC3 levels in the mouse brain
showed that HDAC3 is expressed in discrete regions
with high representation in regions relevant to SCA7
(Figure 5A). In wild type mice we detected highest ex-
pression of HDAC3 in the granular and purkinje cell
layers of the cerebellum (Figure 5A, lower left panel).
There was diffuse yet marked expression of HDAC3 in
the pons and distinct expression of HDAC3 in the hip-
pocampal granular layer (CA3 region), as well as sub-
granular and subventricular zones. HDAC3 was not
highly expressed in the cortex (Figure 5A, upper right
panel).
Given the high expression of HDAC3 in the cerebel-
lum, a region of interest in SCA7, we determined which
cells were expressing HDAC3 by co-labeling with cell-
specific markers (Figure 5B). We found punctate expres-
sion of HDAC3 in neurons of the granular cell layer and
purkinje cell layer. HDAC3 expression was detected
both in the cell bodies and processes of purkinje neu-
rons. Interestingly, HDAC3 had distinct colocalization
with glia, with high-resolution imaging detecting
HDAC3 particularly in the cell bodies and processes of
Bergmann glia, a cerebellum-specific radial glial cell.
HDAC3 expression and enzymatic activity in a SCA7
transgenic mouse model
Distinct colocalization of HDAC3 to cerebellar purkinje
neurons and Bergmann glia, both implicated in mouse
models of SCA7, lead us to explore HDAC3 expression
and also HDAC activity in SCA7 transgenic mice. For
this we used an established transgenic disease model, with
ataxin-7 wild type (SCA7-10Q) or expanded (SCA7-92Q)
expressed under the mouse prion promoter [14,16]. We
used two tissue types most commonly associated with
SCA7 pathology: the cerebellum and retina.















– + + + +––––














































































Figure 3 HDAC3 alters ataxin-7 subcellular localization. (A,B) Expression of ataxin-7 in cytoplasmic and nuclear fractions of HEK293T cells.
Cells were transiently transfected with ataxin-7-10Q (wild type), ataxin-7-92Q (expanded) (A), or the 1–266 N-terminal fragment of wild type and
expanded ataxin-7 (B) and cotransfected with vector control (v) or HDAC3. Lysates were subjected to subcellular fractionation followed by
western blot analysis of nuclear and cytoplasmic fractions. Ataxin-7 antibody revealed the presence of bands corresponding to the wild type,
expanded and stop mutant ataxin-7. Bands of higher molecular weight of ataxin-7 are evident when ataxin-7 is co-expressed with HDAC3
(indicated by asterisks) and present in both nuclear and cytoplasmic fractions. Co-transfection of HDAC3 was confirmed by immunoblotting (data
not shown). To ensure equal loading, immunoblotting with GAPDH was used for the cytoplasmic fractions and poly-ADP ribose (PARP) for the
nuclear fraction. (C) Immunocytochemistry of transfected HEK293T cells. Cells were fixed and stained with antibodies to ataxin-7 conjugated to
Alexa 488 (green), HDAC3 conjugated to Alexa 555 (red), and counterstained with DAPI (blue). Only the ataxin-7 and DAPI expression are shown,
although co-transfection of HDAC3 was determined by visualization of the red track when appropriate. Cells were imaged using confocal
microscopy to elucidate colocalization of ataxin-7 and DAPI. Scale bar represents 5 μm. (D) Quantification of ataxin-7 in nuclear fractions of
HEK293T cells. Cells were transiently transfected with ataxin-7-10Q, ataxin-7-92Q and cotransfected with vector control (v) or HDAC3. Lysates were
subjected to subcellular fractionation followed by western blot analysis of nuclear fractions. Quantification (n = 3) of ataxin-7 levels were normalized
relative to nuclear poly (ADP-ribose) polymerase PARP (1:1000, PARP #9542, Cell Signaling Technology, Boston MA). (E) Cell toxicity determined by
Hoescht staining. Cells were transfected with ataxin-7-10Q or expanded ataxin-7-92Q and visualized via immunocytochemistry following addition of
Hoescht counterstain.
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http://www.molecularneurodegeneration.com/content/8/1/42In the cerebellum, we found that HDAC3 protein levels
were significantly elevated in 9-month-old SCA7-92Q
transgenic mice by western blot analysis (Figure 6A,B).
The increase in expression of HDAC3 is likely muchhigher as we found a significant portion of the protein was
retained in the loading well for the SCA7-92Q lysates
most likely due to aggregation (data not shown). This in-




































































Figure 4 Role of HDAC3 deacetylase activity in ataxin-7 post-translational modification and subcellular localization. (A) Ataxin-7-10Q,
ataxin-7-10Q (1–266), ataxin-7-92Q or ataxin-7-92Q (1–266) were cotransfected with vector control or HDAC3 or a catalytically-inactive mutant of
HDAC3, HDAC3 (H134A/H135A), in HEK293T cells. Western blot analysis of cellular lysates with ataxin-7 (PA1-749) antibody revealed the presence
of bands corresponding to the wild type, expanded and stop mutant ataxin-7. Bands of higher molecular weight that are detected when ataxin-7
is co-expressed with HDAC3 (indicated by asterisks) are also present when ataxin-7 is co-expressed with the catalytically-inactive HDAC3 mutant.
Co-expression of HDAC3 was confirmed by immunoblotting (HDAC3 antibody sc17795; data not shown) and GAPDH was used as a loading
control. (B) Immunocytochemistry of HEK293T cells transiently transfected with ataxin-7-10Q (wild type) or ataxin-7-92Q (expanded), and co-
transfected with HDAC3 or the catalytically-inactive mutant HDAC3 (H134A/H135A). Cells were fixed and stained with antibodies to ataxin-7
conjugated to Alexa 488 (green), HDAC3 conjugated to Alexa 555 (red), and counterstained with DAPI (blue). Cells were imaged using confocal
microscopy to elucidate colocalization of ataxin-7 and HDAC3, which can be detected by yellow co-staining. Scale bar represents 5 μm wild type.
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in SCA7-10Q and SCA7-92Q transgenic mice (Figure 6C).
In wild type animals HDAC3 expression is confined to the
granular cell layer, whereas in transgenic animals HDAC3
is expressed in cells in the molecular layer. In SCA7-92Q
mice there is high expression of HDAC3 in the molecular
layer, with glial cell projections, in the granular cell layer
and also in the soma and projections of the remaining
purkinje cell neurons, despite obvious degeneration of this
cell type consistent with disease progression. In order to
determine whether these protein changes lead to discern-
ible effects on enzymatic activity we examined global
acetylation levels.
In the retina of wild type mice, immunoreactivity of
acetyl-lysine was detected particularly in ganglion cellsand the mixed population of cells in the inner nuclear
layer, with some labeled cells detected in the outer nu-
clear layer (photoreceptors) (Figure 7A). Acetyl-lysine
intensity is decreased in SCA7 transgenic animals, par-
ticularly in the inner and outer nuclear layers. Note that
there is a marked decrease in the number of cells in the
outer and inner nuclear layers in the SCA7-92Q trans-
genic retina, consistent with neurodegeneration of photo-
receptor cells and bipolar/ganglion cells respectively.
Since the level of acetylated proteins is decreased in
the SCA7 mice, we measured deacetylase activity in situ.
Deacetylase activity in the retina of SCA7 transgenic
mice was increased, particularly in the segment layers of
the retina containing photoreceptor rods and cones and






















Figure 5 HDAC3 expression in normal brain and cell-specific expression in the cerebellum. (A) Immunohistochemical staining of sections
from 10.5-month-old non-transgenic control mouse. Fixed tissue sections were probed with an antibody to HDAC3 conjugated to Alexa 488.
Multiple mouse brain regions were captured. Top panel L-R: hippocampus CA3 region; dentate gyrus (DG) and subgranular zone (SGZ); and level
IV-V motor cortex with pyramidal neurons visible; Bottom panel L-R: granular cell layer (GCL) and purkinje cell layer (PCL) of the cerebellum; pons
(Po); caudate putamen (CPu) and subventricular zone (SVZ). Scale bar is 40 μM. (B) Immunohistochemical staining of sections from the cerebellum of
12-month-old non-transgenic control mouse. Fixed tissue sections were probed with an antibody to HDAC3 conjugated to Alexa 488 (green) and
antibodies to various cell-specific markers conjugated to Alexa 555 (red) and counterstained with DAPI (blue). NeuN marks neuronal nuclei and
colabeling with HDAC3 is particularly evident in the upper nuclear layer (arrows), also called the purkinje cell layer (PCL). Calbindin marks purkinje cells
with HDAC3 colocalization detected both in the cell bodies and processes (arrows). GFAP marks neuroglia. Colocalization with HDAC3 is detected in
the processes of Bergman glia (radial glial cells; arrows) in the molecular layer (ML) as well as in astrocytes in the granular cell layer (GCL; arrowhead).
High-resolution image with S100 calcium-binding protein beta (S100β) staining specifically of Bergmann glia cells, with discrete HDAC3 colocalization
in cell bodies and along processes (arrows). Scale bar represents 10 μm.
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http://www.molecularneurodegeneration.com/content/8/1/42containing photoreceptor cell nuclei (marked by arrow-
heads) (Figure 7B). The contribution of sirtuins to this
activity was minimal, as assessed using an HDAC I/II
specific inhibitor. Tissue degeneration is marked in the
SCA7-92Q retinal layers, and this could contribute to a
seemingly more uneven increase in deacetylase levels.Discussion
Many polyglutamine diseases, including SCA7, feature
transcriptional deregulation associated with altered
acetylation state [17,34,35] and cellular toxicity that is
reversible by HDAC inhibition [35]. We have previously






















Figure 6 HDAC3 expression in SCA7 tissue. (A) Protein was extracted from cerebellar tissue of 10.5-month-old MoPrP-flag-92Q-myc transgenic
mice and non-transgenic littermates and subjected to SDS-PAGE and Western blotting with an antibody to HDAC3. GAPDH was used as a
loading control. (B) Protein bands were measured by densitometry and the expression from each genotype is denoted as an average of their
HDAC3 density values (n = 3) normalized to GAPDH and shown as a ratio to non-transgenic values. Bars represent standard deviation from the
mean and asterisks is significance at p < 0.05. (C) Immunohistochemical staining of 9-month-old MoPrP-flag-10Q-myc and MoPrP-flag-92Q-myc
transgenic mice and non-transgenic littermate controls. Fixed cerebellar tissue sections were probed with an antibody to HDAC3 conjugated to
Alexa 488. Scale bar represents 50 μm.
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http://www.molecularneurodegeneration.com/content/8/1/42stability [16]. As ataxin-7 functions in a transcriptional
repressor complex, one proposed mechanism for de-
regulation is aberrant interaction of the polyQ-expanded
protein with factors that regulate acetylation/deacetyla-
tion. In this study we focused on a role for HDAC family
members in ataxin-7 regulation. This is a critical study
given that HDAC inhibitors have been found to amelior-
ate symptoms in many models of trinucleotide repeat dis-
eases, including Huntington’s disease (HD) and Freidrich’s
ataxia [31,32]. Our study indicates that HDAC inhibitors
may also be a target for SCA7 treatment.
In this study we identified HDAC3 as a protein
binding-partner of ataxin-7. We showed that HDAC3
modifies ataxin-7 stability, PTM and subcellular localiza-
tion. Enhanced stability of ataxin-7 could be due to in-
creased production or to reduced degradation. Our
previous study supports the latter conclusion, as we have
previously found that modification of ataxin-7 at lysine-
257, by SUMOylation or acetylation, enhances ataxin-7
stability [16]. Consistent with this study, the PTM-
deficient mutant K257R does not have increased protein
levels or modifications with HDAC3 co-expression. Future
studies may uncover the role of modifications at lysine-
257 on HDAC3 effects. Interestingly, we did not find a dif-
ferential effect on ataxin-7 stability or PTMs using a
catalytically-inactive mutant of HDAC3 compared to the
wild type HDAC3. This indicates that the protein-protein
interaction between ataxin-7 and HDAC3, not its deacety-
lase activity, may be involved in enhancing ataxin-7 levelsand modifications. An alternate explanation is that an-
other HDAC family member that is in complex with
HDAC3 is responsible for modifying ataxin-7.
A major effect of the interaction between ataxin-7 and
HDAC3 is increased levels of the mutant ataxin-7 pro-
tein, with enhanced nuclear expression in cells overex-
pressing HDAC3, concomitant with increased cell
toxicity. Subcellular redistribution may be due to ataxin-
7 shuttling with HDAC3, which is known to undergo
nuclear/cytoplasmic shuttling as part of a transcriptional
corepressor complex [24]. While this effect on localization
may occur via PTM regulation, previous studies have
shown that SUMOylation does not effect subcellular
localization of ataxin-7 [33] and our study further indi-
cates that it is not a result of HDAC enzymatic activity.
As with many neurodegenerative disease proteins,
ataxin-7 is ubiquitously expressed in the brain and yet
the disease manifests in specific brain regions. One
proposition is that regional or cell-specific expression of
interacting proteins, such as HDAC family members,
contributes to selectivity of disease progression [36,37].
Given the varied effects of HDAC3 interaction on
ataxin-7 in vitro, we explored the region-specificity of
HDAC3 in the mouse brain. One previous study ana-
lyzed HDAC3 mRNA in the brain, with high expression
noted in granular cells of the cerebellum and hippocam-
pus [25]. Our study in normal mouse brain found
HDAC3 protein highly expressed in the cerebellum, with
























Figure 7 Acetylation in SCA7 transgenic mice.
(A) Immunohistochemical staining of 10.5-month-old SCA7
transgenic mice and nontransgenic littermate controls. Fixed retinal
tissue sections were probed with an antibody to acetyl-lysine
conjugated to Alexa 488 (green) and counterstained with DAPI
(blue). Scale bar represents 20 μm. (B) HDAC activity in the retina
in vivo. HDAC activity was detected in situ using a deacetylase
substrate, particularly in the pigment epithelium and segment layers of
the retina. Activity due to sirtuins (HDAC III class) was similar to buffer
control (panels shown represent activity in SCA7-10Q tissue) as
detected by HDAC I/II class specific inhibition with TSA (100 μM).
Arrowheads indicate fluorescent cells. ONL: outer nuclear layer; INL:
inner nuclear layer; GCL: ganglion cell layer. Scale bar represents 10 μm.
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men, particularly the subventricular zone. HDAC3
knockout mice are embryonic lethal due to cardiomyop-
athy [26]. However, conditional knockout mice have in-
dicated a role for HDAC3 in brain function as specific
deletion in the hippocampus implicated HDAC3 as a
critical negative regulator of long-term memory formation
[38], consistent with our findings of marked HDAC3expression in the hippocampus. Our expression analysis
suggests HDAC3 may also play a role in neurogenesis,
which is consistent with previous studies showing that
HDAC3 is expressed in developing rat brain and that
HDAC activity is crucial for determining cell progenitor
fate [39].
Given the high expression of HDAC3 in the cerebel-
lum, and the major degeneration of this region in SCA7,
we determined the cell-specific expression of HDAC3.
Neuronal and glial-cell markers showed HDAC3 to be
highly expressed in the Purkinje cell layer, with distinct
colocalization with Bergmann glial cell soma and pro-
cesses. SCA7 animal models have revealed that polyQ-
expanded ataxin-7 dysfunction in either neurons or glia
of the cerebellum leads to behavioural phenotypes and
neurodegeneration, but that rescue of ataxin-7 function in
both cell types is required to reverse the SCA7 phenotype
[40,41]. This non-cell autonomous feature indicates that
SCA7 degeneration resulting from ataxin-7 dysfunction
results from interactions in purkinje cells and Bergmann
glia, both of which our study shows express HDAC3.
Given this remarkable expression pattern we next
assessed HDAC3 expression in a well-characterized SCA7
transgenic mouse model. In the cerebellum we found in-
creased HDAC3 protein levels in the SCA7 polyQ-
expanded transgenic mice. In cells we showed that
HDAC3 and ataxin-7 interaction was enhanced with
polyQ-expanded ataxin-7, which we hypothesize could
lead to increased stability of the HDAC3 protein in SCA7.
Interestingly, increased expression of HDAC3 protein has
recently been shown to be highly toxic to cerebellar and
cortical neurons but not to non-neuronal cells [27], which
may explain why neurons selectively die despite our evi-
dence for high expression of HDAC3 in glia.
In the retina we found decreased acetyl-lysine levels in
photoreceptor cell body layers, concomitant with in-
creased deacetylase activity. These changes are consist-
ent with previous studies that evaluated promoter
occupancy of the SCA7-92Q mice relevant to histone
H3 acetylation and found a significant decrease with dis-
ease progression at 6 and 11 weeks of age [8]. Further, in
HD mouse models histone H3 acetylation is decreased
during disease [42]. However, our study is particularly
interesting as it is known that HDAC activity requires
binding to cofactors [22] and previous studies have show
that HDAC3 interaction with a transcriptional corepres-
sor, N-CoR, increased HDAC activity [21]. HDAC3
interaction with ataxin-7, a constituent component of
transcriptional corepressor complexes, could also poten-
tially increase HDAC activity, enhancing toxicity.
From our findings we hypothesize that HDAC3 inter-
action with polyQ-expanded ataxin-7, particularly in the
pathological regions in SCA7, increases HDAC3 stability
and HDAC activity, leading to transcriptional deregulation,
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ectly analyze this role by looking at the affect of altered
HDAC3 levels in a SCA7 transgenic model, particularly on
behavioural phenotypes, cerebellar degeneration and mor-
bidity. A pathogenic role for HDAC3 in SCA7 must be
further assessed in transgenic mouse models before any
conclusions are drawn, although it is consistent with previ-
ous studies that HDAC inhibitors with high affinity to
HDAC3 complexes [43] may ameliorate deficits in polyQ
disease models. In a mouse model of Freidich’s Ataxia,
treatment with HDAC inhibitors with an HDAC3 prefer-
ence enhanced motor coordination and ameliorated mul-
tiple pathological deficits [32]. Using a similar compound
another study found that HDAC inhibition reduced behav-
ioural phenotypes and pathology as well as partially cor-
recting transcriptional deregulation in a mouse model of
HD [31] although other studies have questioned the speci-
ficity of the drug or did not reproduce all the beneficial ef-
fects found in the first study [44,45]. Furthermore,
HDAC3 knockdown in a C. elegans HD model suppressed
neurotoxicity [30], consistent with our findings of HDAC3
enhancing cellular toxicity. In contrast to these latter re-
ports, one study found no benefit of partial HDAC3
knockdown in a genetic cross with an HD mouse model
[46]. However, recent studies suggest that the wild-type
Htt binds to HDAC3 and dissociation of HDAC3 when
mutant Htt is present is essential for toxicity [47]. We
propose that the physical interaction of HDAC3 with
ataxin-7, and other expansion disease proteins resulting in
cellular toxicity (perhaps with distinct mechanisms), makes
HDAC3 a target for intervention in these diseases. In sup-
port of a role for HDAC3 in trinucelotide repeat diseases,
a recent report found that HDAC3 promotes instability,
leading to expansions of trinucleotide repeats in cell and
animal models [48].
In summary, we found that HDAC3 and ataxin-7
physically interact, leading to increased stability, enhan-
cing post-translational modifications and increased sub-
cellular localization of ataxin-7. Furthermore, we
detected altered HDAC3 levels, acetyl-lysine levels and
deacetylase activity in a transgenic mouse model of
SCA7 and found HDAC3 to be highly expressed in both
neurons and glia in the cerebellum of nontransgenic and
SCA7 transgenic mice. Further studies will elucidate the
physical nature of the interaction between ataxin-7 and
HDAC3, the effect of polyQ-expansion on the inter-
action and levels of HDAC3 and on SCA7 pathogenesis,
and whether alteration of HDAC3 levels may be a viable
pharmacological target. With reports of HDAC3 binding
to three different ataxin proteins [18,19,47], and HDAC3-
specific inhibition ameliorating disease in animal models
[31,32,34], our study adds to growing evidence for
HDAC3 modulation as a target for multiple neurodegen-
erative diseases.Methods
SCA7 transgenic mice
Production and characterization of SCA7 transgenic
mice, with ataxin-7 containing 10 or 92 CAG repeats
expressed under the direction of the prion promoter
(PrP) has been described previously [14]. Expression
levels for PrP-mycFlag-SCA7-10Q-Line A305 and PrP-
mycFlag-SCA7-92Q-Line B306 were determined in the
initial characterization [16]. Transgenic mice in the PrP-
mycFlag-SCA7-92Q-Line 306 overexpress ataxin-7 two-
fold relative to endogenous levels, have retinal pathology
by 12-weeks of age and have a shortened lifespan
(9 months). At the Buck Institute for Research on Aging,
an AAALAC international B306 accredited institution
(Unit #001070), all procedures were approved by the In-
stitutional Animal and Use Committee (A4213-01).
Plasmid constructs
Ataxin-7 cDNA was cloned into pcDNA3.1 (Invitrogen,
Carlsbad, CA), with inserts containing either 10 or 92
CAG repeats, and a stop mutant created by site-directed
mutagenesis at amino acid position 266, as previously
published [16]. Site-directed mutagenesis was performed
to generate a K257R amino acid substitution as previ-
ously described [16]. All constructs were sequenced to
confirm that the appropriate mutation was introduced
and CAG repeat length was not altered. For co-expression
studies, plasmids encoding HDACs 2–8 were purchased
from Origene (Rockville, MD): HDAC2 (#SC110918),
HDAC3 (#SC112704), HDAC6 (#SC111132), HDAC8
(#SC321829) or Addgene (Cambridge, MA): HDAC4
(#13821), HDAC5 (#13822). HDAC7 plasmid was a gift
from Dr. Hung-Yin Kao and the HDAC3 catalytically-
inactive mutant construct (H134A/H135A substitutions)
was a gift from Dr. Eric Verdin.
Cell culture, transfection and harvesting
HEK293T cells were cultured in DMEM (Mediatech,
Manassas, VA) containing 1% penicillin/streptomycin
(25 units/mL each) and 10% heat-inactivated fetal bovine
serum (DMEM complete) unless otherwise specified.
Transient transfections were performed using lipofecta-
mine 2000 (L2000, Invitrogen) according to manufac-
turer’s instructions. For total protein extractions, cells
were seeded in 6-well dishes at approximately 5 × 105
cells/well. Each well was transfected with 4 μg total
DNA by L2000 in DMEM lacking serum and antibiotics.
Following 72 h incubation at 37°C, cells were harvested,
lysed in Mammalian Protein Extraction Reagent (MPER;
Thermo Scientific, Rockford, IL) containing protease in-
hibitors (Complete Mini, Roche Applied Science, Mann-
heim, Germany), sonicated and spun at 12,000 g for 15
min to remove undigested cellular components. Protein
concentration was determined using a BCA assay
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says, 6 × 106 cells were seeded in 10 cm plates, trans-
fected with 25 μg DNA by L2000 in serum-free DMEM
and incubated for 72 h at 37°C. For immunocytochem-
istry, including cellular toxicity assays, cells were seeded
in 8-well slides at 6–10 × 104 cells/well. Each well was
transfected with 1.2 μg total DNA in serum-free DMEM
and processed following 48 h incubation at 37°C.
Subcellular fractionation
For subcellular fractionation protein assays, transfected
HEK293T cells were harvested and nuclear and cytoplas-
mic fractions were separated using the NE-PER Nuclear
and Cytoplasmic Extraction Kit (Thermo Fisher Scien-
tific, Rockford Illinois) according to the manufacturer’s
instructions. Briefly, cells were harvested in trypsin-
EDTA (Mediatech) and approximately 6 × 106 cells were
spun at 500 g for 3 min. Supernatant was removed and
approximately 50 μL of cells recovered. Cytoplasmic Ex-
traction Reagents (CERI and CERII) were added to these
cells, which were then vortexed at high-speed and spun
at 16,000 g for 5 min at 4°C. The cytoplasmic protein
fraction was recovered from the supernatant fraction.
The pellet was resuspended in Nuclear Extraction buffer
(NER) by intermittent high-speed vortexing over 40 min
and the sample was centrifuged at 16,000 g for 10 min
at 4°C. The nuclear protein was separated into the
supernatant fraction. Protein concentrations of the nu-
clear and cytoplasmic fractions were determined using a
BCA assay and 10 μg of protein were subjected to west-
ern blotting.
Immunoprecipitation
Pull-down assays of transfected HEK293T cells were
undertaken using Protein G Sepharose beads (GE
Healthcare, Uppsla, Sweden), washed and used accord-
ing to the manufacturer’s instructions. Lysates (500 μg)
were pre-cleared by incubation with beads without the
antibody for 1 h at 4°C with rotation. Pre-cleared lysates
were incubated with primary antibody, 3 μL ataxin-7
(PA1-749) or 5 μL HDAC3 (sc-17795), overnight with
rotation at 4°C. Antibody-incubated lysates were trans-
ferred to the bead slurry and immunoprecipitated for
2 h at 4°C with rotation. Immunodepleted sample was
removed after centrifugation at high-speed for 3 min.
Bound beads were then washed rigorgously in lysis buf-
fer (MPER with proteinase inhibitors, as described
above) and once in HEPES made up in lysis buffer with-
out proteinase inhibitors to remove salts. Beads were
precipitated by boiling in water with loading buffer and
DTT (10 mM) for 10 min and spun briefly to collect
beads. Half of the precipitate was used for western blot-
ting, along with immunodepleted samples and 10 μg of
input protein.Western blotting of transfected cells
For western blotting of transfected HEK293T cells, 10 μg
of protein containing DTT (10 mM) was heated at 95°C
for 10 min. Samples were subjected to SDS-PAGE using
4-12% NuPage Bis-Tris (Invitrogen) gels under reducing
conditions in MES SDS running buffer (Invitrogen). Gels
were run at 200 V for 70 min, transferred to 0.45 μM
nitrocellulose membrane (Whatman, Dassel, Germany)
in NuPage transfer buffer (Invitrogen) with 10% metha-
nol and western transfer undertaken at a constant
350 mA for 1 h. Membranes were blocked in TBS with
0.1% Tween 20 (TBS-T) containing 5% milk for 1 h. Pri-
mary antibodies were diluted in blocking solution at
1:1000 for ataxin-7 (PA1-749, Thermo Scientific, Rock-
ford, IL), 1:100 for HDAC3 (sc-17795, Santa Cruz Bio-
technology), 1:5000 for GAPDH (MAB734; Chemicon,
Temecula, CA), 1:1000 for β-actin (#4967S; Millipore,
Billerica, MA) and 1:500 for poly-ADP ribose (PARP;
SA-253, Enzo Life Science, Farmingdale, NY). Immuno-
blots were developed with a peroxidase-conjugated sec-
ondary antibody and enhanced chemiluminescence.
Immunocytochemistry
Cells were fixed by adding 8% paraformaldehyde directly
to culture medium to a final concentration of 4%. Cells
were incubated for 20 min with gentle agitation then
washed with PBS at room temperature (RT). Cells were
permeabilized in 0.25% Triton in TBS for 15 min,
washed in TBS, and blocked in 10% NDS in TBS for 1 h.
Primary antibody was incubated with cells overnight at
4°C after dilution in TBS containing 1% BSA at 1:200 for
ataxin-7 (K antibody: [14,16] and 1:20 for HDAC3 (sc-
17795, Santa Cruz Biotechnology). Cells were then
washed in TBS and secondary antibody in TBS contain-
ing 1% BSA was applied for 1 h at RT. Ataxin-7 was la-
beled with 1:500 Alexa 488 donkey anti-rabbit and
HDAC3 was labeled with 1:500 Alexa 555 donkey anti-
mouse. For the cell toxicity assay, 1:5000 Hoescht 33342
(10 mg/ml; H21492, Invitrogen) was included in the sec-
ondary antibody incubation. A no primary antibody
control was included in each experiment to detect back-
ground fluorescence. Cells were washed, dried and
mounted with ProlongGold +/− DAPI (Invitrogen).
Slides were cured overnight. Confocal images were ob-
tained using a Zeiss LSM 510 NLO microscope and
Zeiss LSM Image Browser software. Laser settings used
were 488 Ar to capture ataxin-7, 543 He/Ne for HDAC3
and Chameleon Ultra tuned to 780 nm for DAPI acqui-
sition. Following capture, all images were compiled in
Adobe Photoshop using identical parameters for each
channel. For the cellular toxicity assays, 100 cells/field
were counted in two separate fields for each transfec-
tion condition and this was duplicated in a separate
transfection.
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transgenic mouse tissue
Protein was extracted from the cerebellum of 9-month
old mice: PrP-mycFlag-SCA7-10Q-Line A305, PrP-mycFlag-
SCA7-92Q-Line B306 and non-transgenic littermate
controls. Cerebella were homogenized in 10 ml/g tissue of
Tissue Protein Extraction Reagent (TPER; Thermo Scien-
tific) containing protease inhibitors, DNase (10 U/mL),
MgCl2 (1.2 mM), epoxymycin (1 μM) phosphatase inhibi-
tors (Phosphatase Inhibitor Cocktail Set II, Calbiochem,
La Jolla, CA) and HDAC inhibitors (50 μM TSA, 30 μM
sodium butyrate, 30 mM nicotinamide). Tissue was
homogenized, snap frozen at −80°C overnight, defrosted
at RT to enhance cell lysis, sonicated and spun at 12,000 g
for 15 min. Supernatant and pellets were kept for analysis.
Protein concentration was determined using a BCA assay
(Pierce, Rockford, IL) and 40 μg of proteins were run on
polyacrylamide gels in MES buffer for 70 min at 200 V.
Proteins were transferred to a 0.45 μm nitrocellulose
(Whatman, Dassel, Germany) membrane at 20 V over-
night (14 h) at 4°C in NuPAGE tranfer buffer with 10%
methanol. Band intensity was quantified using NIH
ImageQuant TL v2005. Membranes were blocked in TBS
with 0.1% Tween 20 (TBS-T) containing 5% milk for 1 h.
Primary antibodies were diluted in blocking solution at
1:1000 for ataxin-7 (PA1-749; Affinity Bioreagents), 1:2500
for HDAC3 (ab7030, Abcam, Cambridge, MA) and 1:1000
tubulin (T4026; Sigma-Aldrich, St Louis, MI) Immu-
noblots were developed with a peroxidase-conjugated
secondary antibody and enhanced chemiluminescence
(Pierce).
Immunohistochemistry of SCA7 transgenic mouse
brain sections
SCA7 mice were perfused with PBS and then 4% PFA in
PBS. The eyes and brain were removed and embedded
in paraffin blocks. Brain and retinal tissue was cut into
7 μM sections on a microtome. Paraffin-embedded
sections were washed with xylene twice for 5 min to
deparaffinize the tissue. Sections were re-hydrated in
consecutive ethanol washes (100% to 70%) before resus-
pension in 1X Tris-buffered saline for 15 min. All
washes were performed at RT. For antigen retrieval, sec-
tions were microwaved in 10 mM citrate buffer, pH 6.0,
for 5 min at 40% power in a 1100 W microwave oven
(Sanyo). Sections were allowed to cool in the same buf-
fer for 20 min at RT and were then transferred to TBS
for 10 min. For immunostaining, sections were blocked
in 10% normal donkey serum in TBS for 1 h at RT.
Ataxin-7 (1:200; K antibody), HDAC3 (1:20 for retinal
tissue and 1:500 for cerebellar tissue; Abcam ab7030),
acetyl-lysine (1:250; Abcam ab21623), glial fibrillary
acidic protein (GFAP; 1:500; Sigma G3893), neuronal
nuclear marker (NeuN; 1:200; Millipore MAB377),calbindin (1:500; C9848 Sigma) and S100 calcium bind-
ing protein beta (S100β; 1:1000; Abcam ab11178) pri-
mary antibodies were diluted in 1% BSA in TBS and
incubated overnight at 4°C. All subsequent steps were
performed at RT. Sections were washed in TBS. Alexa
488 donkey anti-rabbit secondary antibody (1:500 in 1%
BSA in TBS) was applied to sections for 1 h. Following
incubation in secondary antibody, sections were washed
in TBS and mounted in ProlongGold with DAPI. Slides
were cured overnight. Epifluorescence images were cap-
tured on a Nikon Eclipse E800 microscope. Confocal
images were obtained using a Zeiss LSM 510 NLO
microscope and Zeiss LSM Image Browser software.
HDAC activity assay
In situ HDAC activity was determined in retinal sections
using the Fluor-de- Lys™ HDAC flurometric activity assay
(Enzo Life Sciences International Inc, Plymouth Meeting,
PA) previously modified for use in tissue [49]. Briefly,
paraformaldehyde-fixed retinal sections (7 μM) were incu-
bated with deacetylase substrate (200 μM) in assay buffer
(50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl,
1 mM MgCl2) for 3 h at RT. HDAC I/II -specific inhibitor,
trichostatin A (100 μM; Sigma, Steinham, Germany), was
added to some sections to determine the influence of
sirtuin activity. Buffer-only controls were included in all
experiments. After incubation, sections were washed
briefly in PBS and then fixed in methanol at −80°C for
20 min. Freshly prepared Fluor-de- Lys™ developer (0.5X)
in assay buffer was added and sections were coverslipped
and immediately visualized on a Nikon Eclipse E800
microscope in the DAPI range (excitation 350–380 nm;
emission 440–460 nm).
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